Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pomalidomide + Zn-DDC
- Development stage
- Preclinical
- Lead developer
- The Royal Wolverhampton NHS Trust
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pomalidomide + Zn-DDC is an investigational combination therapy being studied for the treatment of hematological malignancies, including multiple myeloma. Pomalidomide is a second-generation immunomodulatory drug (IMiD) that exerts antineoplastic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis in malignant cells. It is approved for use in relapsed/refractory multiple myeloma and other indications. Zn-DDC (zinc diethyldithiocarbamate), also known as Imuthiol, has demonstrated toxicity to cancer stem cells in preclinical studies and may target hypoxia-related pathways such as NF-kappaB signaling implicated in cancer cell survival. The combination aims to leverage the anti-myeloma activity of pomalidomide with the potential cancer stem cell targeting properties of Zn-DDC to improve outcomes in patients with difficult-to-treat blood cancers[5]. Clinical trials are ongoing to assess safety and efficacy.
- Other names
- pomalidomide and Zn-DDCpomalidomide plus Imuthiol
02
Targets
CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)
Beyond the preview
Go deeper on pomalidomide + Zn-DDC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pomalidomide + Zn-DDC.